Adding immunotherapy to chemotherapy for stage III colon cancer (dMMR) cuts the risk of recurrence or death by 50%. A landmark phase III trial finds that 86% of patients remained disease-free after 3 years, establishing a new global "standard of care" for this specific genetic subtype. - 内容目录